Novo Nordisk AS' incoming top exec Lars Fruergaard Jørgensen thinks the company can launch a new product every year, while remaining focused on offering differentiated products in the competitive diabetes market – but the biggest challenge will remain the level of payer pressure and competition, he said in an interview with Scrip.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?